| Date | Title | Description |
| 27.01.2025 | Sphere Fluidics launches Cyto-Mine Chroma and announces Early Access Program | Researchers invited to gain early access to next-generation platform to optimize functional single-cell analysis workflows across expanded applications in life science R&D
Cambridge, UK, 27th January 2025: Sphere Fluidics, a leading pro... |
| 10.12.2024 | Sphere Fluidics launches Cyto-Cellect® Fc Fusion Assay Kit to expedite cell line development for fusion proteins | Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.
Cambridge, UK: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell anal... |
| 01.10.2024 | Sphere Fluidics announces Cyto-Mine Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development | Next generation of industry-leading Cyto-Mine platform will offer new capabilities to optimize single-cell analysis workflow efficiency
Opens up new, multiplexed assays and applications for antibody discovery and cell line development, and ... |
| 04.06.2024 | Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows | Next-generation assay provides a rapid and cost-effective solution to quantify IgG production in single cells
Cambridge, UK, 04 June, 2024: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell anal... |
| 22.04.2024 | Sphere Fluidics appoints Edward Rayner as Non-Executive Director | - |
| 11.04.2022 | Frost & Sullivan Hails Sphere Fluidics for Enabling Efficient, Faster, and More Cost-effective Single-cell Analysis with Its Microfluidic Platforms | The flexible and easy-to-use microfluidic platforms easily adapt to customers' unique research needs, boost throughput and efficiency, and enhance customers' single-cell research capabilities.
SAN ANTONIO, April 11, 2022 /PRNewswire/ -- Fro... |
| 29.10.2021 | UK biotech scaleup Sphere Fluidics secures €34.2M to develop and commercialise single cell analysis systems | Cambridge, UK-based Sphere Fluidics, a company that develops products for use in single-cell analysis and characterisation, and provides associated collaborative R&D services, has raised $40M (approx €34.28M) in a fresh round of funding... |
| 28.10.2021 | Sphere Fluidics closes a $40 million funding round | Sphere Fluidics closes a $40 million funding round
28-10-2021
Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it h... |
| 28.10.2021 | GWC facilitates a £30m investment into portfolio company Sphere Fluidics | GWC is pleased to announce that in conjunction with Peel Hunt we facilitated a £30m investment into Sphere Fluidics by two global health care funds, Redmile and Sofinnova. This will enable to company to accelerate its global roll out of its... |
| 28.10.2021 | Sphere Fluidics closes a $40 million funding round led by Soffinova Partners and Redmile Group | - |
| 17.05.2021 | Sphere Fluidics announces enhanced Cyto-Mine capability and performance | Sphere Fluidics announces enhanced Cyto-Mine capability and performance
17-05-2021
Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, an... |
| 17.05.2021 | Sphere Fluidics announces enhanced Cyto-Mine capability and performance | Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, and synthetic biology workflows.
Sphere Fluidics, a company developing single cell an... |
| 25.08.2020 | Deadlines loom for prestigious business competitions | Deadlines loom for prestigious business competitions
25-08-2020
Cambridge companies keen to raise their profile should consider entering prestigious business award competitions, the deadlines for which are fast approaching.
Applications clo... |
| 21.04.2020 | Sphere Fluidics receives Queen’s Award for Enterprise | Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, has be honored with a Queen’s Award for Enterprise for Innovation. The award recognises the Company’s excellence in ... |
| 21.04.2020 | Sphere Fluidics receives Queen’s Award for Enterprise | Sphere Fluidics receives Queen’s Award for Enterprise
21-04-2020
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, has be honored with a Queen’s Award for Enterprise ... |
| 14.02.2020 | Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics | Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for... |
| 14.02.2020 | Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics | Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics
14-02-2020
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet te... |
| 21.08.2019 | Sphere Fluidics expands into additional facility at Granta Park | Sphere Fluidics expands into additional facility at Granta Park
21-08-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new ... |
| 21.08.2019 | Sphere Fluidics expands into additional facility at Granta Park | Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities suppo... |
| 10.06.2019 | Sphere Fluidics closes a $4.8 million USD (£3.7 million) funding round | Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a to... |
| 10.06.2019 | Sphere Fluidics closes a $4.8 million USD (£3.7 million) funding round | Sphere Fluidics closes a $4.8 million USD (£3.7 million) funding round
10-06-2019
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed... |
| 10.06.2019 | Sphere Fluidics Raises $4.8M Funding Round | Sphere Fluidics, a Cambridge, England, UK-based company commercializing single cell analysis systems, closed an additional tranche of investment of $2.9m (£2.2m), securing a total of $4.8m (£3.7m).
The round was led by Greenwood Way Capital... |
| 05.06.2019 | GWC leads a £3.7m investment into Cambridge University spin out Sphere Fluidics | Sphere Fluidics is a Cambridge University spin out with world leading technology which makes it possible to screen tens of millions of cells. It provides you with the best chance of finding that rare and valuable variant, whether it’s a dis... |
| 27.02.2019 | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards
27-02-2019
Cofinitive is delighted to announce it has been shortlisted among the brightest and best of elite Cambridge-based companies in the upcoming B... |
| 29.01.2019 | Sphere Fluidics Closes $2M Funding Round | Sphere Fluidics, a Cambridge, England, UK-based company commercializing single cell analysis systems, closed a $2m (circa £1.5m) funding round.
Backers included Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymark... |
| 29.01.2019 | Sphere Fluidics closes $2 million round | - |
| 29.01.2019 | Sphere Fluidics closes $2m (£1.5m) investment round | Sphere Fluidics closes $2m (£1.5m) investment round
29-01-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed a $2 million (circ... |
| 28.11.2017 | Geneva Biotech and Sphere Fluidics receive €1.6 million grant from Eurostars | |
| 17.07.2017 | Sphere Fluidics and partners win InnovateUK grant to develop the world’s first desktop genome | Sphere Fluidics and partners win InnovateUK grant to develop the world’s first desktop genome
17-07-2017
Sphere Fluidics Limited and its partners have just won a £1 million grant to develop a novel automated single cell genome engineering p... |
| 23.02.2016 | Mills & Reeve advises Sphere Fluidics on $7million fundraising | Mills & Reeve advises Sphere Fluidics on $7million fundraising
23-02-2016
National law firm Mills & Reeve has advised Cambridge-based life sciences company Sphere Fluidics Limited on its latest investment round, securing $7 million ... |
| 10.02.2016 | Sphere Fluidics Secures $7M | Sphere Fluidics Limited, a Cambridge, UK-based developer of a single cell analysis system, secured $7m in the first close of its latest funding.
The round, which remains open, is being led by an Asian Corporate investor with participation f... |
| 23.05.2013 | Mills & Reeve advises Sphere Fluidics on £1.65 million series A fundraising | Mills & Reeve advises Sphere Fluidics on £1.65 million series A fundraising
23-05-2013
Leading national law firm Mills & Reeve has advised Cambridge-based life sciences company Sphere Fluidics Limited on its recent £1.65 million ser... |
| 20.02.2013 | Sphere Fluidics successfully closes a £1.6 million Series A investment round | Sphere Fluidics, an early-stage, Cambridge-based company focusing on developing novel products and services for single cell analysis, has just completed a £1.6 million investment round.
The investment syndicate was led by 24Haymarket and in... |
| 20.02.2013 | Sphere Fluidics successfully closes a £1.6 million Series A investment round | Sphere Fluidics successfully closes a £1.6 million Series A investment round
20-02-2013
Sphere Fluidics, an early-stage, Cambridge-based company focusing on developing novel products and services for single cell analysis, has just completed... |
| 27.03.2012 | Microfluidic expert Dolomite launches novel surface coating agent for droplet microfluidics | Microfluidic expert Dolomite launches novel surface coating agent for droplet microfluidics
27-03-2012
After the successful launch of Pico-Surf™ surfactants earlier this year, Dolomite, a world leader in the design and manufacture of microf... |
| 27.03.2012 | Microfluidic expert Dolomite launches novel surface coating agent for droplet microfluidics | After the successful launch of Pico-Surf™ surfactants earlier this year, Dolomite, a world leader in the design and manufacture of microfluidic systems and devices, has announced the release of Pico-Glide™, a novel surface coating agent fac... |
| - | Cambridge Enterprise | A huge thank you to all the team at Cambridge Enterprise for an excellent University of Cambridge Enterprise Fund investor evening yesterday at Emmanuel College.
Investee companies presenting included:
Aqdot (highlighted in the FT yesterday... |
| - | Sphere Fluidics – Parkwalk closes further funding round | We have closed a follow-on investment in Sphere Fluidics for the Opportunities Fund. This follows the UCEFs investing previously. |
| - | Sphere Fluidics – University of Cambridge Enterprise Fund III closes further funding round | We have closed an investment, in a $7m funding round, in Sphere Fluidics for the University of Cambridge Enterprise Fund III. This follows the UCEFs I and II investing previously. The investment round has been led by an Asian corporate inve... |
| - | Sphere Fluidics – Parkwalk closes further funding round | We have closed an investment, in the first tranche of a financing round of up to £2m, in Sphere Fluidics for the University of Cambridge Enterprise Fund II and the final investment for Parkwalk Fund IV. This follows the UoCEF I investing in... |
